Results 241 to 250 of about 58,783 (322)

RNA Regulatory Networks: Key Hubs in the Panorama of Cancer and Emerging Therapeutic Targets

MedComm, Volume 7, Issue 3, March 2026.
RNA regulatory networks play a crucial role in the initiation and progression of cancer through various modes of RNA interactions. Notably, circulating RNAs have emerged as potential biomarkers, while targeted interventions in RNA regulatory networks facilitate precise therapeutic strategies. ABSTRACT Cancer is a global health challenge. The initiation
Xuan Yin, Zengkan Du, Shuya Jiang, Yan Liao, Changli Wang, Jiaqi Li, Haoling Zhang, Ting‐Ting Wei, Wangzheqi Zhang, Zui Zou   +9 more
wiley   +1 more source

The mechanism by which methylase METTL3 affects intramuscular fat deposition. [PDF]

Poult Sci
Yu B, Li K, Li X, Zhang J.
europepmc   +1 more source

Chromatin Accessibility in Cancer: Biological Functions, Mechanisms, Therapeutic Potential, and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Cancer remains the leading cause of mortality worldwide, and drug resistance further underscores the urgent need for innovative therapeutic strategies. Chromatin, a stable yet highly dynamic nucleoprotein complex, serves as the primary carrier of genetic material in eukaryotic cells.
Wentao Xia, Min Jiang, Yefei Huang, Kun Ding, Yansu Chen   +4 more
wiley   +1 more source

The orchestrated interplay between DNA methylation and N6-methyladenosine modification: <i>status quo</i> and future perspectives. [PDF]

PeerJ
Yang J, Liao J, Mo BW, Gao Y, Chen YX, Gu Y, Liang MM, Li HM.   +7 more
europepmc   +1 more source

The NLRP3 Inflammasome: Mechanisms of Activation, Regulation, and Therapeutic Opportunities

MedComm, Volume 7, Issue 3, March 2026.
Diverse diseases converge on NLRP3. We depict a discovery‐to‐clinic track: high‐throughput/phenotypic screens, structure‐guided design, and modality innovation (allosteric inhibitors, interface blockers, degraders) deliver third‐generation, disease‐tailored NLRP3 control.
Chan Zou, Shilong Jiang, Hui Li, Kai Zhao, Dongshen Cao, Guoping Yang   +5 more
wiley   +1 more source

High-stoichiometry m⁶A sites are evolutionarily conserved. [PDF]

RNA
Pike HNC, Schwartz S.
europepmc   +1 more source

Protein Lactylation in Cancer: Mechanisms and Therapeutic Targets

MedComm, Volume 7, Issue 3, March 2026.
This schematic illustrates the central role of lactylation, a lactate‐derived posttranslational modification, in linking metabolic reprogramming to cancer progression and therapy resistance. At its core, lactylation modulates proteins, influenced by metabolic shifts and environmental factors.
Qianying Ouyang, Qianyu Hu, Caiqin Wang, Yizi He, Ruolan Zeng, Yajun Li, Chang Su, Guige Lu, Xueting Zhu, Ling Xiao, Hui Zhou   +10 more
wiley   +1 more source

m⁶A demethylase-driven reprogramming of leukemia-associated macrophages predicts improved outcomes in acute myeloid leukemia. [PDF]

Front Immunol
Shi Z, Xia Y, Zhang M, Peng Y, An Y, Zhu Q, Sun T.   +6 more
europepmc   +1 more source

RNA‐Binding Proteins and Ferroptosis in Cancer: Mechanism and Therapeutic Implications

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Ferroptosis critically influences cancer cell fate and represents a promising therapeutic strategy. Emerging evidence identifies RNA‐binding proteins (RBPs) as key post‐transcriptional regulators of ferroptosis. The figure summarizes ferroptosis‐related RBPs across cancers: blue RBPs act as tumor suppressors by promoting ferroptosis, whereas red RBPs ...
Linlin Chang, Bin Lu, Haotian Shang, Wanjing Ding, Chunhua Wei, Xiaotian Qi, Pengxing He   +6 more
wiley   +1 more source

The Roles and Implications of m6A Methylation in Radiotherapy for Gastrointestinal Tumors. [PDF]

Dose Response
Bi J, Hu W, Bian H, Cheng W.
europepmc   +1 more source